



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended

(5 U.S.C. App), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Medication Ingestion Compliance (2231)

Date: May 14, 2013

Time: 1:00 PM to 2:00 PM

Agenda: To review and evaluate contract proposals

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Affairs
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Blvd., Room 4238, MSC 9550
Bethesda, MD 20892-9550
301-402-6626
gm145a@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Confirming Compliance (2232)

Date: May 14, 2013

Time: 2:00 PM to 3:00 PM

Agenda: To review and evaluate contract proposals

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Affairs
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Blvd., Room 4238, MSC 9550
Bethesda, MD 20892-9550
301-402-6626
gm145a@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Confirming Compliance with Experimental Pharmacotherapy
Treatment of Drug Abuse (2227)

Date: May 14, 2013

Time: 3:00 PM to 4:00 PM

Agenda: To review and evaluate contract proposals

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Affairs
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Blvd., Room 4238, MSC 9550
Bethesda, MD 20892-9550
301-402-6626
gm145a@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: May 3, 2013

Michelle Trout, Program Analyst
Office of Federal Advisory Committee Policy

[FR Doc. 2013-11104 Filed 05/09/2013 at 8:45 am; Publication Date: 05/10/2013]